Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $45.00

Viridian Therapeutics (NASDAQ:VRDN) had its target price upped by Royal Bank Of Canada from $41.00 to $45.00 in a research note released on Thursday morning, Marketbeat.com reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Wells Fargo & Company dropped their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. The Goldman Sachs Group reissued a “buy” rating and set a $40.00 price target on shares of Viridian Therapeutics in a research report on Thursday. Jefferies Financial Group began coverage on Viridian Therapeutics in a research report on Monday, August 25th. They issued a “buy” rating and a $44.00 price objective for the company. Needham & Company LLC reduced their target price on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Finally, BTIG Research restated a “buy” rating and issued a $61.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, November 4th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.78.

Viridian Therapeutics Trading Down 0.2%

NASDAQ VRDN opened at $27.44 on Thursday. The company has a market cap of $2.24 billion, a PE ratio of -7.16 and a beta of 0.72. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $28.60. The stock has a 50 day moving average of $21.30 and a 200-day moving average of $17.54.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.48. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $16.21 million. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. Viridian Therapeutics’s revenue was up 81993.0% on a year-over-year basis. On average, equities research analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Fairmount Funds Management Llc purchased 454,545 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the acquisition, the director owned 3,914,458 shares in the company, valued at approximately $86,118,076. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.58% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank increased its holdings in shares of Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after buying an additional 840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after acquiring an additional 876 shares in the last quarter. Knights of Columbus Asset Advisors LLC grew its position in Viridian Therapeutics by 2.4% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company’s stock worth $1,282,000 after acquiring an additional 1,386 shares during the last quarter. Swiss National Bank increased its holdings in Viridian Therapeutics by 1.3% in the 2nd quarter. Swiss National Bank now owns 108,900 shares of the company’s stock worth $1,522,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.